128 related articles for article (PubMed ID: 10336272)
21. Application of nitric oxide for a case of veno-occlusive disease after peripheral blood stem cell transplantation.
Kajiume T; Yoshimi S; Nagita A; Kobayashi K; Kataoka N
Pediatr Hematol Oncol; 2000; 17(7):601-4. PubMed ID: 11033737
[TBL] [Abstract][Full Text] [Related]
22. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J
Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534
[TBL] [Abstract][Full Text] [Related]
23. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation.
Toh HC; McAfee SL; Sackstein R; Cox BF; Colby C; Spitzer TR
Bone Marrow Transplant; 1999 Oct; 24(8):891-5. PubMed ID: 10516702
[TBL] [Abstract][Full Text] [Related]
24. Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
Keilholz U; Körbling M; Fehrentz D; Bauer H; Hunstein W
Cancer; 1989 Aug; 64(3):641-5. PubMed ID: 2568164
[TBL] [Abstract][Full Text] [Related]
25. Programmed haploidentical hematopoietic stem cell infusion combined with systemic chemotherapy improves the outcomes of patients with refractory or relapsed lymphoma.
Zhao HX; Sun WJ; Li J; Hu HL; Ai HS
Leuk Lymphoma; 2015 Jan; 56(1):270-3. PubMed ID: 24730537
[No Abstract] [Full Text] [Related]
26. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Pedersen-Bjergaard J; Pedersen M; Myhre J; Geisler C
Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
[TBL] [Abstract][Full Text] [Related]
27. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of adult T-cell leukemia/lymphoma: progresses in the chemotherapy and stem cell transplantation].
Tsukasaki K
Rinsho Ketsueki; 2004 Mar; 45(3):195-201. PubMed ID: 15103932
[No Abstract] [Full Text] [Related]
29. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
[TBL] [Abstract][Full Text] [Related]
30. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis.
Xun CQ; McSweeney PA; Boeckh M; Storb RF; Broudy VC; Thompson JA
Blood; 1999 Nov; 94(9):3273-6. PubMed ID: 10610124
[No Abstract] [Full Text] [Related]
31. Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease?
Ustun C; Smith A; Cayci Z; Courville EL; Corbacioglu S; Akin C; Horny HP; Valent P; Devine S; Weisdorf DJ
Eur J Haematol; 2016 Jun; 96(6):655-7. PubMed ID: 26679533
[No Abstract] [Full Text] [Related]
32. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Recchia F; Candeloro G; Rosselli M; Bratta M; Pasta V; D'Orazi V; Fumagalli LA; Rea S
Anticancer Res; 2015 Dec; 35(12):6847-53. PubMed ID: 26637906
[TBL] [Abstract][Full Text] [Related]
34. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation.
Ohashi K; Tanabe J; Watanabe R; Tanaka T; Sakamaki H; Maruta A; Okamoto S; Aotsuka N; Saito K; Nishimura M; Oh H; Matsuzaki M; Takahashi S; Yonekura S
Am J Hematol; 2000 May; 64(1):32-8. PubMed ID: 10815785
[TBL] [Abstract][Full Text] [Related]
35. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C
Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
[TBL] [Abstract][Full Text] [Related]
36. [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
Jost LM; Honegger HP; Stahel RA
Schweiz Med Wochenschr; 2000 Jan; 130(3):60-9. PubMed ID: 10683881
[TBL] [Abstract][Full Text] [Related]
37. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
[TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study.
Hjermstad MJ; Evensen SA; Kvaløy SO; Fayers PM; Kaasa S
J Clin Oncol; 1999 Feb; 17(2):706-18. PubMed ID: 10080617
[TBL] [Abstract][Full Text] [Related]
39. Coexisting or underlying risk factors of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients receiving prophylaxis.
Gökce M; Kuskonmaz B; Cetin M; Uckan Cetinkaya D; Tuncer M
Exp Clin Transplant; 2013 Oct; 11(5):440-6. PubMed ID: 24128137
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation.
Qiao J; Fu J; Fang T; Huang Y; Mi H; Yang N; Chen C; Xu K; Zeng L
Exp Mol Pathol; 2015 Feb; 98(1):73-8. PubMed ID: 25533545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
